Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies.

Furthermore, their subgroup analysis revealed a notable trend wherein patients with L858R mutations appeared to derive greater PFS benefit from the four-drug regimen compared with those harboring 19-del mutations.

also in 2,105 other papers

Subgroup analyses ( Supplementary Figure 7B ) revealed that, although the median OS for the ICI combination regimen subgroup was numerically superior to that of the dual ICI and ICI monotherapy subgroups, these differences did not reach statistical significance.

also in 75,278 other papers